Literature DB >> 27520998

Successful treatment of recurrent renal stones with Cinacalcet in a patient with primary hyperparathyroidism.

Priyesh Chauhan1, Neil J Gittoes2, Tarekegn Geberhiwot2.   

Abstract

A man aged 72 years with long-standing primary hyperparathyroidism (HPT), a background of recurrent bilateral renal stones and failed parathyroid surgery is described. During the 27 months preceding treatment, episodes of renal colic became increasingly frequent and he required multiple surgical interventions. Given the lack of medical therapies to definitively treat his symptoms, he was started on a trial of the calcimimetic, Cinacalcet. Cinacalcet has previously been shown to reduce hypercalcaemia in patients with primary HPT. Despite this, there is a paucity of evidence to suggest that its use is associated with a long-term reduction in urinary calcium excretion and renal stone recurrence. In our case, within 4 months of starting treatment, serum and urinary calcium had normalised and parathyroid hormone concentrations were within reference ranges. To date, over a 50-month treatment period, there has been a complete cessation in stone formation, and no further urological intervention has been required. 2016 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27520998      PMCID: PMC4986140          DOI: 10.1136/bcr-2016-216311

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  9 in total

1.  Prevalence of kidney stones and vertebral fractures in primary hyperparathyroidism using imaging technology.

Authors:  Cristiana Cipriani; Federica Biamonte; Aline G Costa; Chiyuan Zhang; Piergianni Biondi; Daniele Diacinti; Jessica Pepe; Sara Piemonte; Alfredo Scillitani; Salvatore Minisola; John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2015-02-03       Impact factor: 5.958

2.  Calcium kidney stones are associated with a haplotype of the calcium-sensing receptor gene regulatory region.

Authors:  Giuseppe Vezzoli; Annalisa Terranegra; Teresa Arcidiacono; Giovanni Gambaro; Luciano Milanesi; Ettore Mosca; Laura Soldati
Journal:  Nephrol Dial Transplant       Date:  2010-01-12       Impact factor: 5.992

3.  Use of cinacalcet in nephrolithiasis associated with normocalcemic or hypercalcemic primary hyperparathyroidism: results of a prospective randomized pilot study.

Authors:  Simone Brardi; Gabriele Cevenini; Tiziano Verdacchi; Giuseppe Romano; Roberto Ponchietti
Journal:  Arch Ital Urol Androl       Date:  2015-03-31

4.  Development of nephrolithiasis in a renal transplant patient during treatment with Cinacalcet.

Authors:  Catherine M Seager; Titte R Srinivas; Stuart M Flechner
Journal:  Ann Transplant       Date:  2013-01-22       Impact factor: 1.530

Review 5.  Hyperparathyroidism.

Authors:  William D Fraser
Journal:  Lancet       Date:  2009-07-11       Impact factor: 79.321

6.  Clinical Use of Cinacalcet in MEN1 Hyperparathyroidism.

Authors:  V J Moyes; J P Monson; S L Chew; S A Akker
Journal:  Int J Endocrinol       Date:  2010-05-26       Impact factor: 3.257

7.  Experience with cinacalcet in primary hyperparathyroidism: results after 1 year of treatment.

Authors:  Inés Luque-Fernández; Antonia García-Martín; Alessandra Luque-Pazos
Journal:  Ther Adv Endocrinol Metab       Date:  2013-06       Impact factor: 3.565

8.  Effect of cinacalcet on urine calcium excretion and supersaturation in genetic hypercalciuric stone-forming rats.

Authors:  D A Bushinsky; K Laplante; J R Asplin
Journal:  Kidney Int       Date:  2006-05       Impact factor: 10.612

9.  Allosteric modulation of the calcium-sensing receptor.

Authors:  Anders A Jensen; Hans Bräuner-Osborne
Journal:  Curr Neuropharmacol       Date:  2007-09       Impact factor: 7.363

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.